Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 2—February 2023

Age-Stratified Model to Assess Health Outcomes of COVID-19 Vaccination Strategies, Ghana

Sylvia K. Ofori, Jessica S. Schwind, Kelly L. Sullivan, Gerardo Chowell, Benjamin J. Cowling, and Isaac Chun-Hai FungComments to Author 
Author affiliations: Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA (S.K. Ofori); Georgia Southern University Jiann-Ping Hsu College of Public Health, Statesboro, Georgia, USA (S.K. Ofori, K.L. Sullivan, I.C.-H. Fung); Georgia Southern University Institute for Health Logistics and Analytics, Statesboro (J.S. Schwind); Georgia State University School of Public Health, Atlanta, Georgia, USA (G. Chowell); WHO Collaborating Centre for Infectious Disease Epidemiology and Control, The University of Hong Kong School of Public Health, Pokfulam, Hong Kong (B.J. Cowling)

Main Article

Table 1

Parameter values for age-stratified SEPIARD-V COVID-19 model to assess health outcomes of COVID-19 vaccination strategies, Ghana*

Parameter Symbol Value References
Mean latency period which is the period from exposure to infectiousness
1.85 d
Abbasi et al. (18), Liu et al. (19)
Mean duration of being infectious and symptomatic
15.7 d
Cai et al. (20), Xing et al. (21)
Mean duration of being infectious and asymptomatic
7.25 d
Ma et al. (22), Byrne et al. (23)
Mean duration of being infectious and presymptomatic
2.9 d
Tindale et al. (24), Byrne et al. (23)
Reproduction number for the initial strain
Armachie et al., unpub. data,
Reproduction number for the Delta strain
Pearson et al., unpub. data,
Probability of exposed person becoming presymptomatically infected
Chen et al. (25), Buitrago-Garcia et al. (26)
Vaccine efficacy against infection
Knoll et al. (27)
Relative transmissibility of asymptomatic persons
CDC (28)
Relative transmissibility of presymptomatic persons
CDC (28)
Mean duration of immunity after vaccination
182 d
Iacobucci (29)
Mean duration of immunity after natural infection
365 d
Good and Hawkes (30)
Age-specific case-fatality ratio
0.002 for <25 y, 0.005 for 25–64 y, 0.048 for ≥65 y
Our World in Data (January 26, 2021–November 12, 2021; 22), Lawal (31)
Daily vaccination rate v Varied by 0.00009–0.0163977 d–1 per person Estimated

*CDC, Centers for Disease Control and Prevention; SEPIARD-V, Susceptible-Exposed-Presymptomatic-Symptomatic-Asymptomatic-Recovered-Dead-Vaccinated.

Main Article

  1. Ghana Health Service. COVID-19 Ghana's outbreak response management updates. 2022 [cited 2023 Jan 06].
  2. Ofori  SK, Schwind  JS, Sullivan  KL, Cowling  BJ, Chowell  G, Fung  IC-H. Transmission dynamics of COVID-19 in Ghana and the impact of public health interventions. Am J Trop Med Hyg. 2022;107:1759. DOIPubMedGoogle Scholar
  3. Quakyi  NK, Agyemang Asante  NA, Nartey  YA, Bediako  Y, Sam-Agudu  NA. Ghana’s COVID-19 response: the Black Star can do even better. BMJ Glob Health. 2021;6:e005569. DOIPubMedGoogle Scholar
  4. Alhassan  RK, Aberese-Ako  M, Doegah  PT, Immurana  M, Dalaba  MA, Manyeh  AK, et al. COVID-19 vaccine hesitancy among the adult population in Ghana: evidence from a pre-vaccination rollout survey. Trop Med Health. 2021;49:96. DOIPubMedGoogle Scholar
  5. World Health Organization Africa. More COVID-19 vaccines arrive in Ghana. 2021. [cited 2022 Dec 6].
  6. Ghana Health Service. COVID-19 Ghana’s outbreak response management updates. 2020 [cited 2022 Feb 21].
  7. Botwe  BO, Antwi  WK, Adusei  JA, Mayeden  RN, Akudjedu  TN, Sule  SD. COVID-19 vaccine hesitancy concerns: Findings from a Ghana clinical radiography workforce survey. Radiography (Lond). 2022;28:53744. DOIPubMedGoogle Scholar
  8. Quashie  PK, Mutungi  JK, Dzabeng  F, Oduro-Mensah  D, Opurum  PC, Tapela  K, et al. Trends of SARS-CoV-2 antibody prevalence in selected regions across Ghana. Wellcome Open Res. 2021;6:173. DOIGoogle Scholar
  9. Alagoz  O, Sethi  AK, Patterson  BW, Churpek  M, Alhanaee  G, Scaria  E, et al. The impact of vaccination to control COVID-19 burden in the United States: A simulation modeling approach. PLoS One. 2021;16:e0254456. DOIPubMedGoogle Scholar
  10. Moghadas  SM, Vilches  TN, Zhang  K, Wells  CR, Shoukat  A, Singer  BH, et al. The impact of vaccination on coronavirus disease 2019 (COVID-19) outbreaks in the United States. Clin Infect Dis. 2021;73:225764. DOIPubMedGoogle Scholar
  11. Matrajt  L, Eaton  J, Leung  T, Brown  ER. Vaccine optimization for COVID-19: Who to vaccinate first? Sci Adv. 2021;7:eabf1374. DOIPubMedGoogle Scholar
  12. Mumtaz  GR, El-Jardali  F, Jabbour  M, Harb  A, Abu-Raddad  LJ, Makhoul  M. Modeling the impact of COVID-19 vaccination in Lebanon: a call to speed-up vaccine roll out. Vaccines (Basel). 2021;9:697. DOIPubMedGoogle Scholar
  13. Bubar  KM, Reinholt  K, Kissler  SM, Lipsitch  M, Cobey  S, Grad  YH, et al. Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science. 2021;371:91621. DOIPubMedGoogle Scholar
  14. University of British Columbia Department of Zoology. COVID-19 models lecture. 2020 [cited 2020 Nov 15].
  15. Wei  WE, Li  Z, Chiew  CJ, Yong  SE, Toh  MP, Lee  VJ. Presymptomatic Transmission of SARS-CoV-2 - Singapore, January 23-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:4115. DOIPubMedGoogle Scholar
  16. Li  Y, Shi  J, Xia  J, Duan  J, Chen  L, Yu  X, et al. Asymptomatic and symptomatic patients with non-severe coronavirus disease (COVID-19) have similar clinical features and virological courses: a retrospective single center study. Front Microbiol. 2020;11:1570. DOIPubMedGoogle Scholar
  17. Zhao  H, Lu  X, Deng  Y, Tang  Y, Lu  J. COVID-19: asymptomatic carrier transmission is an underestimated problem. Epidemiol Infect. 2020;148:e116-e.
  18. Abbasi  Z, Zamani  I, Mehra  AHA, Shafieirad  M, Ibeas  A. Optimal control design of impulsive SQEIAR epidemic models with application to COVID-19. Chaos Solitons Fractals. 2020;139:110054. DOIPubMedGoogle Scholar
  19. Liu  Z, Magal  P, Seydi  O, Webb  G. A COVID-19 epidemic model with latency period. Infect Dis Model. 2020;5:32337. DOIPubMedGoogle Scholar
  20. Cai  Q, Huang  D, Ou  P, Yu  H, Zhu  Z, Xia  Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy. 2020;75:174252. DOIPubMedGoogle Scholar
  21. Xing  YH, Ni  W, Wu  Q, Li  WJ, Li  GJ, Wang  WD, et al. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019. J Microbiol Immunol Infect. 2020;53:47380. DOIPubMedGoogle Scholar
  22. Ma  S, Zhang  J, Zeng  M, Yun  Q, Guo  W, Zheng  Y, et al. Epidemiological parameters of COVID-19: cases series study. J Med Internet Res. 2020;22:e19994. DOIPubMedGoogle Scholar
  23. Byrne  AW, McEvoy  D, Collins  AB, Hunt  K, Casey  M, Barber  A, et al. Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. BMJ Open. 2020;10:e039856. DOIPubMedGoogle Scholar
  24. Tindale  LC, Stockdale  JE, Coombe  M, Garlock  ES, Lau  WYV, Saraswat  M, et al. Evidence for transmission of COVID-19 prior to symptom onset. eLife. 2020;9:e57149. DOIPubMedGoogle Scholar
  25. Chen  M, Li  M, Hao  Y, Liu  Z, Hu  L, Wang  L. The introduction of population migration to SEIAR for COVID-19 epidemic modeling with an efficient intervention strategy. Inf Fusion. 2020;64:2528. DOIPubMedGoogle Scholar
  26. Buitrago-Garcia  D, Egli-Gany  D, Counotte  MJ, Hossmann  S, Imeri  H, Ipekci  AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med. 2020;17:e1003346-e.
  27. Knoll  MD, Wonodi  C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397:724. DOIPubMedGoogle Scholar
  28. Centers for Disease Control and Prevention. Pandemic planning scenarios. 2020 [cited 2020 Nov 12].
  29. Iacobucci  G. Covid-19: Protection from two doses of vaccine wanes within six months, data suggest. BMJ. 2021;374:n2113. DOIPubMedGoogle Scholar
  30. Good  MF, Hawkes  MT. The interaction of natural and vaccine-induced immunity with social distancing predicts the evolution of the COVID-19 Pandemic. MBio. 2020;11:e0261720. DOIPubMedGoogle Scholar
  31. Lawal  Y. Africa’s low COVID-19 mortality rate: A paradox? Int J Infect Dis. 2021;102:11822. DOIPubMedGoogle Scholar
  32. Lopez Bernal  J, Andrews  N, Gower  C, Gallagher  E, Simmons  R, Thelwall  S, et al. Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant. N Engl J Med. 2021;385:58594. DOIPubMedGoogle Scholar
  33. le Polain de Waroux  O, Cohuet  S, Ndazima  D, Kucharski  AJ, Juan-Giner  A, Flasche  S, et al. Characteristics of human encounters and social mixing patterns relevant to infectious diseases spread by close contact: a survey in Southwest Uganda. BMC Infect Dis. 2018;18:172. DOIPubMedGoogle Scholar
  34. Kiti  MC, Kinyanjui  TM, Koech  DC, Munywoki  PK, Medley  GF, Nokes  DJ. Quantifying age-related rates of social contact using diaries in a rural coastal population of Kenya. PLoS One. 2014;9:e104786. DOIPubMedGoogle Scholar
  35. Trentini  F, Guzzetta  G, Galli  M, Zardini  A, Manenti  F, Putoto  G, et al. Modeling the interplay between demography, social contact patterns, and SARS-CoV-2 transmission in the South West Shewa Zone of Oromia Region, Ethiopia. BMC Med. 2021;19:89. DOIPubMedGoogle Scholar
  36. Central Intelligence Agency. The world factbook. 2020 [cited 2022 Jan 15].
  37. Anaadem  P. Ghana: population hits 30.8 million—Greater Accra most populous region—GSS. Ghana Today. 2021 Sep 22 [cited 2022 Dec 6].
  38. Foy  BH, Wahl  B, Mehta  K, Shet  A, Menon  GI, Britto  C. Comparing COVID-19 vaccine allocation strategies in India: A mathematical modelling study. Int J Infect Dis. 2021;103:4318. DOIPubMedGoogle Scholar
  39. Ko  Y, Lee  J, Kim  Y, Kwon  D, Jung  E. COVID-19 vaccine priority strategy using a heterogenous transmission model based on maximum likelihood estimation in the Republic of Korea. Int J Environ Res Public Health. 2021;18:6469. DOIPubMedGoogle Scholar
  40. Diarra  M, Kebir  A, Talla  C, Barry  A, Faye  J, Louati  D, et al.; REPAIR consortium. Non-pharmaceutical interventions and COVID-19 vaccination strategies in Senegal: a modelling study. BMJ Glob Health. 2022;7:e007236. DOIPubMedGoogle Scholar
  41. Buckner  JH, Chowell  G, Springborn  MR. Dynamic prioritization of COVID-19 vaccines when social distancing is limited for essential workers. Proc Natl Acad Sci U S A. 2021;118:e2025786118. DOIPubMedGoogle Scholar
  42. Chapman  LAC, Shukla  P, Rodríguez-Barraquer  I, Shete  PB, León  TM, Bibbins-Domingo  K, et al. Risk factor targeting for vaccine prioritization during the COVID-19 pandemic. Sci Rep. 2022;12:3055. DOIPubMedGoogle Scholar
  43. Acheampong  T, Akorsikumah  EA, Osae-Kwapong  J, Khalid  M, Appiah  A, Amuasi  JH. Examining vaccine hesitancy in sub-saharan Africa: a survey of the knowledge and attitudes among adults to receive COVID-19 vaccines in Ghana. Vaccines (Basel). 2021;9:814. DOIPubMedGoogle Scholar
  44. Nikolovski  J, Koldijk  M, Weverling  GJ, Spertus  J, Turakhia  M, Saxon  L, et al. Factors indicating intention to vaccinate with a COVID-19 vaccine among older U.S. adults. PloS one. 2021;16:e0251963-e.
  45. Dembek  ZF, Schwartz-Watjen  KT, Swiatecka  AL, Broadway  KM, Hadeed  SJ, Mothershead  JL, et al. Coronavirus disease 2019 on the heels of Ebola virus disease in West Africa. Pathogens. 2021;10:1266. DOIPubMedGoogle Scholar
  46. Andrews  N, Stowe  J, Kirsebom  F, Toffa  S, Rickeard  T, Gallagher  E, et al. Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant. N Engl J Med. 2022;386:153246. DOIPubMedGoogle Scholar

Main Article

Page created: December 06, 2022
Page updated: January 21, 2023
Page reviewed: January 21, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.